CNR1 and Parkinson disease: We found two studies where ∆9‐THCV showed promise as an anti‐epileptic agent and protected neurons in two models of Parkinson's disease, while García et al. (2011) suggested ∆9‐THCV mediated some of its protective effects by acting at CB1 and CB2 receptors, the possible mechanisms of action of ∆9‐THCV was largely unexplored (García et al., 2011; Hill et al., 2010).